跳至主要内容
临床试验/NCT01189864
NCT01189864终止不适用

Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas

Cxlusa14 个研究点 分布在 1 个国家目标入组 3,493 人开始时间: 2010年2月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
终止
发起方
Cxlusa
入组人数
3,493
试验地点
14
主要终点
Increase the biomechanical and biochemical stability of the cornea by inducing additional cross-links within

研究概览

简要总结

The purpose of this study is to evaluate the efficacy of ultraviolet-A (UVA)-induced cross-linking of corneal collagen (CXL) as a method to increase the biomechanical and biochemical stability of the cornea by inducing additional cross-links within or between collagen fibers using UVA light and the photo- mediator riboflavin. The purpose of this study is to generate data for presentation at medical meetings and for peer-review publication. The data generated by this study will not be submitted to the FDA to support commercialization of these riboflavin drops.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
12 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 12 years of age or older
  • Diagnosis of keratoconus, FFKC, post-LASIK ectasia, or pellucid marginal degeneration or forme fruste pellucid marginal degeneration (FFPMD).
  • Diagnosis of FFKC
  • History of Radial Keratotomy with fluctuating vision
  • Ability to provide written informed consent
  • Likely to complete all study visits
  • Minimum corneal thickness of at least 300 Measured by ultrasound or Pentacam
  • At least 6 months since last corneal surgery (Intacs/PRK/LASIK/Epi-LASIK/LASEK)

排除标准

  • Severe corneal scarring that markedly affects vision
  • Contraindications to any study medications or their components
  • Pregnancy or breast feeding
  • Active Herpes Corneal Disease

研究组 & 干预措施

Ciprofloxicin or Vigamox or other.

干预措施: Ciprofloxicin or Vigamox or other. (Drug)

Nonsteroidal (Acular, Voltaren Xibrom, etc)

干预措施: Nonsteroidal (Acular, Acuvail, Voltaren Xibrom, etc) (Drug)

Steroid (FML, Pred Forte, Flarex, etc.)

干预措施: Steroid (FML, Pred Forte, Flarex, etc.) (Drug)

结局指标

主要结局

Increase the biomechanical and biochemical stability of the cornea by inducing additional cross-links within

时间窗: 1 year

次要结局

  • increase the biomechanical and biochemical stability of the cornea between collagen fibers using UVA light and the photo- mediator riboflavin(1 year)

研究者

发起方
Cxlusa
申办方类型
Industry
责任方
Sponsor

研究点 (14)

Loading locations...

相似试验